Sorrento Therapeutics Inc (SRNE) Given Average Rating of “Buy” by Brokerages
Sorrento Therapeutics Inc (NASDAQ:SRNE) has been given an average recommendation of “Buy” by the six analysts that are covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $12.00.
Several research analysts recently commented on SRNE shares. Oppenheimer set a $7.00 price target on Sorrento Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 10th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Sorrento Therapeutics in a research note on Thursday, August 24th.
Sorrento Therapeutics (NASDAQ SRNE) opened at $2.32 on Wednesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.54 and a current ratio of 0.54. Sorrento Therapeutics has a one year low of $1.50 and a one year high of $6.08.
ILLEGAL ACTIVITY WARNING: “Sorrento Therapeutics Inc (SRNE) Given Average Rating of “Buy” by Brokerages” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/06/sorrento-therapeutics-inc-srne-given-average-rating-of-buy-by-brokerages-2.html.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
Receive News & Ratings for Sorrento Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.